{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:04:37Z","timestamp":1789718677614,"version":"4.0.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Previous summaries of GY-13 have lacked transparent literature-search methods, reproducible material definitions, chemical-characterization status, or critical evidence grading, limiting their scientific utility.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review critically evaluates what the published GY-13 literature shows and does not show regarding antidepressant pharmacology, material reproducibility, clinical evidence, and safety. It also reformulates the Heyi-Neuroplasticity-Stress (HNS) framework as a testable translational hypothesis rather than as a confirmed mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This critical scoping review was reported using a PRISMA-informed approach, with PRISMA-ScR, the Four Pillars of Best Practice in Ethnopharmacology, and ConPhyMP used as reporting and interpretive frameworks. Searches were rerun on 3 June 2026 in PubMed\/MEDLINE and CNKI, supplemented by public bibliographic records and citation checking. Thirty records were identified; after deduplication and screening, 12 studies or contextual records were retained. The review was not prospectively registered, screening and extraction were not performed by two independent reviewers, and no validated design-specific risk-of-bias tool was applied. These limitations preclude designation as a fully systematic review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The available evidence supports the possibility that GY-13 affects depression-related behavioral and molecular endpoints in stress-based animal models, including cAMP\/PKA\/CREB\/BDNF signaling, HPA-axis feedback, monoamine signaling, inflammatory-oxidative pathways, and chemokine-axis findings. However, the reproducibility of these findings is limited by incomplete reporting of batch identity, voucher\/authentication data, manufacturing details, HPLC\/UPLC or LC-MS fingerprints, marker-metabolite quantification, dose-response structure, and randomization\/blinding. Human evidence remains preliminary and insufficient for definitive clinical-efficacy claims.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GY-13 is best treated as a hypothesis-generating multi-component intervention requiring chemically defined batches, strict ConPhyMP documentation, independent preclinical replication, and well-powered clinical trials with standardized safety monitoring. The HNS framework may guide future biomarker-enriched research only if tested prospectively with transparent materials and methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1912784","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:58:28Z","timestamp":1789718308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Review Areca Thirteen Pill (GY-13) for depression: a ConPhyMP-Informed critical review of material definition, pharmacological evidence, and translational Heyi-neuroplasticity-stress hypotheses"],"prefix":"10.3389","volume":"17","author":[{"given":"Narisu","family":"Dai","sequence":"first","affiliation":[{"name":"Baotou Medical College, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Bao","sequence":"additional","affiliation":[{"name":"Baotou Medical College, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[{"name":"Baotou Medical College, Inner Mongolia University of Science and Technology","place":["Baotou, China"]},{"name":"Department of Mongolian Medicine, Inner Mongolia Minzu University","place":["Tongliao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","first-page":"189","article-title":"Preliminary analysis of the relationship between Mongolian medicine Heyi and depression","volume":"33","author":"Bai","year":"2014","journal-title":"Beijing J. Tradit. Chin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1007\/s12035-023-03855-1","article-title":"Areca thirteen pill improves depression in rat by modulation of the chemokine\/chemokine receptor axis","volume":"61","author":"Bai","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"B3","first-page":"117179","article-title":"Arecae semen: a comprehensive review of botany, traditional uses, phytochemistry, pharmacology, toxicology, and quality control","volume":"319","author":"Bai","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B4","first-page":"7873","article-title":"Effects of Mongolian medicine areca thirteen pill on hypothalamic-pituitary-adrenal axis negative feedback in chronic stress depression model rats","volume":"18","author":"Bao","year":"2014","journal-title":"Chin. J. Tissue Eng. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"115310","DOI":"10.1016\/j.jep.2022.115310","article-title":"Mongolian medicine areca thirteen pill (GY-13) improved depressive syndrome via upregulating cAMP\/PKA\/CREB\/BDNF signaling pathway","volume":"293","author":"Cai","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"B6","first-page":"1372","article-title":"Comparative analysis on the efficacy of Binlang Shisanwei pill (Gaoyou-13) and its mechanism of treating depression from the perspective of Chinese and Mongolian medicine theory","volume":"14","author":"Chen","year":"2019","journal-title":"World Chin. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.biopsych.2006.02.013","article-title":"A neurotrophic model for stress-related mood disorders","volume":"59","author":"Duman","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.oooo.2016.04.018","article-title":"Oral submucous fibrosis: review on mechanisms of malignant transformation","volume":"122","author":"Ekanayaka","year":"2016","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","article-title":"Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications","volume":"246","author":"Felger","year":"2013","journal-title":"Neuroscience"},{"key":"B11","doi-asserted-by":"publisher","first-page":"112230","DOI":"10.1016\/j.jep.2019.112230","article-title":"Best practice in research: overcoming common challenges in phytopharmacological research","volume":"246","author":"Heinrich","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"953205","DOI":"10.3389\/fphar.2022.953205","article-title":"Best practice in the chemical characterisation of extracts used in pharmacological and toxicological research: the ConPhyMP guidelines","volume":"13","author":"Heinrich","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B13","first-page":"678","article-title":"Discussion on the relationship between the onset time of Mongolian medical Heyi disease and depression","volume":"9","author":"Li","year":"2016","journal-title":"Glob. Tradit. Chin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e42217","DOI":"10.1097\/MD.0000000000042217","article-title":"Investigating the mechanism of action of the Mongolian medicine areca thirteen pill (GY-13) in treating major depressive disorder based on integrated pharmacology","volume":"104","author":"Li","year":"2025","journal-title":"Med. Baltim."},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tins.2008.06.006","article-title":"The HPA axis in major depression: classical theories and new developments","volume":"31","author":"Pariante","year":"2008","journal-title":"Trends Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: a convergence of mechanisms","volume":"33","author":"Pittenger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jep.2013.12.022","article-title":"What is in a name? The need for accurate scientific nomenclature for plants","volume":"152","author":"Rivera","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1554448","DOI":"10.3389\/fphar.2025.1554448","article-title":"Exploring traditional Mongolian materia medica: the path of progress from tradition to modernity","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B21","first-page":"11","article-title":"Clinical efficacy of Mongolian medicine areca thirteen pill combined with sertraline in treating mild to moderate depression","volume":"18","author":"Tai","year":"2025","journal-title":"Clin. Ration. Drug Use"},{"key":"B22","first-page":"1946","article-title":"Effects of areca thirteen Pill on AC-cAMP-PKA signaling pathway in hippocampus and prefrontal cortex of depressive rats","volume":"39","author":"Tong","year":"","journal-title":"Chin. J. Chin. Mater. Med."},{"key":"B23","first-page":"1916","article-title":"Textual research on the formulation of Mongolian medicine Areca Thirteen Pill (Gaoyou-13)","volume":"16","author":"Tong","year":"","journal-title":"World Sci. Technol.-Mod. Tradit. Chin. Med."},{"key":"B24","first-page":"53","article-title":"Effects of Mongolian medicine Areca Thirteen Pill (Gaoyou-13) on behavior and monoamine neurotransmitters in different brain regions of depression model rats","volume":"4","author":"Tong","year":"","journal-title":"Acta Chin. Med. Pharmacol."},{"key":"B25","first-page":"42","article-title":"Observation on the effects of Areca Thirteen Pill on behavior and hypothalamic-pituitary-adrenal axis in chronic stress depression model rats","volume":"31","author":"Tong","year":"2012","journal-title":"J. South-Cent. Minzu Univ. Nat. Sci. Ed."},{"key":"B26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1177\/00220345221092751","article-title":"Areca nut and oral cancer: evidence from studies conducted in humans","volume":"101","author":"Warnakulasuriya","year":"2022","journal-title":"J. Dent. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1026219","DOI":"10.3389\/fphar.2022.1026219","article-title":"Processed lateral root of Aconitum carmichaelii debx.: a review of cardiotonic effects and cardiotoxicity on molecular mechanisms","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1912784\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:58:30Z","timestamp":1789718310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1912784\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":28,"alternative-id":["10.3389\/fphar.2026.1912784"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1912784","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1912784"}}